Acura Pharmaceuticals (STU:HD4B) Enterprise Value: €1.27 Mil (As of Jul. 03, 2026) ***


STU:HD4B Acura Pharmaceuticals Inc STU:HD4B
16 GF Score
Price €0.20
View Full Analysis

What is Acura Pharmaceuticals Enterprise Value?

Acura Pharmaceuticals STU:HD4B 16 Enterprise Value is €1.27 Mil as of Jul. 03, 2026. GuruFocus rates STU:HD4B with a GF Score™ of 16/100.

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Acura Pharmaceuticals's Enterprise Value is €1.27 Mil. Acura Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2021 was €-0.57 Mil. Therefore, Acura Pharmaceuticals's EV-to-EBIT ratio for today is -2.22.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Acura Pharmaceuticals's Enterprise Value is €1.27 Mil. Acura Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2021 was €-0.49 Mil. Therefore, Acura Pharmaceuticals's EV-to-EBITDA ratio for today is -2.57.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Acura Pharmaceuticals's Enterprise Value is €1.27 Mil. Acura Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2021 was €1.31 Mil. Therefore, Acura Pharmaceuticals's EV-to-Revenue ratio for today is 0.96.

EV-to-OCF is calculated as Enterprise Value divided by its Cash Flow from Operations. As of today, Acura Pharmaceuticals's Enterprise Value is €1.27 Mil. Acura Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2021 was €-0.64 Mil. Therefore, Acura Pharmaceuticals's EV-to-OCF ratio for today is -1.98.

EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Acura Pharmaceuticals's Enterprise Value is €1.27 Mil. Acura Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2021 was €-0.64 Mil. Therefore, Acura Pharmaceuticals's EV-to-FCF ratio for today is -1.98.

*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.


Acura Pharmaceuticals  (STU:HD4B) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Acura Pharmaceuticals's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=1.266/-0.569
=-2.22

Acura Pharmaceuticals's current Enterprise Value is €1.27 Mil.
Acura Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.57 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Acura Pharmaceuticals's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=1.266/-0.492
=-2.57

Acura Pharmaceuticals's current Enterprise Value is €1.27 Mil.
Acura Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.49 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Acura Pharmaceuticals's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=1.266/1.312
=0.96

Acura Pharmaceuticals's current Enterprise Value is €1.27 Mil.
Acura Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.31 Mil.

4. EV-to-OCF is calculated as Enterprise Value divided by its Cash Flow from Operations.

Acura Pharmaceuticals's EV-to-OCF for today is:

EV-to-OCF=Enterprise Value (Today)/Cash Flow from Operations (TTM)
=1.266/-0.639
=-1.98

Acura Pharmaceuticals's current Enterprise Value is €1.27 Mil.
Acura Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.64 Mil.

5. EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow.

Acura Pharmaceuticals's EV-to-FCF for today is:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=1.266/-0.639
=-1.98

Acura Pharmaceuticals's current Enterprise Value is €1.27 Mil.
Acura Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.64 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Acura Pharmaceuticals Enterprise Value Related Terms


Acura Pharmaceuticals Enterprise Value Historical Data

* Premium members only.

The historical data trend for Acura Pharmaceuticals's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Acura Pharmaceuticals Enterprise Value Chart

Acura Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.22 4.90 8.03 7.67 23.55

Acura Pharmaceuticals Quarterly Data
Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.67 10.14 26.53 23.76 23.55

STU:HD4B vs VFRM, THCT, CBGL: Enterprise Value Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Acura Pharmaceuticals's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acura Pharmaceuticals Enterprise Value vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Acura Pharmaceuticals's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Acura Pharmaceuticals's Enterprise Value falls into.


STU:HD4B
16GF Score
Acura Pharmaceuticals Inc STU:HD4B
Enterprise Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Acura Pharmaceuticals Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Acura Pharmaceuticals's Enterprise Value for the fiscal year that ended in Dec. 2021 is calculated as

Acura Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2021 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Enterprise Value →
What does a Enterprise Value of €1.27 Mil mean?
Acura Pharmaceuticals (STU:HD4B) has a Enterprise Value of €1.27 Mil as of Jul. 03, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Acura Pharmaceuticals and its competitors.
Is Acura Pharmaceuticals' Enterprise Value too high?
Acura Pharmaceuticals' current Enterprise Value is €1.27 Mil. Overall, Acura Pharmaceuticals has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Acura Pharmaceuticals' Enterprise Value compare to VFRM and THCT?
Acura Pharmaceuticals' Enterprise Value of €1.27 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Acura Pharmaceuticals and its competitors. Acura Pharmaceuticals's current Enterprise Value is €1.27 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acura Pharmaceuticals stock overvalued right now?
Acura Pharmaceuticals (STU:HD4B) has a current Enterprise Value of €1.27 Mil. The current Enterprise Value is €1.27 Mil. Acura Pharmaceuticals' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Acura Pharmaceuticals (STU:HD4B), the current Enterprise Value is €1.27 Mil as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Acura Pharmaceuticals Business Description

Address 616 N. North Court, Suite 120, Palatine, IL, USA, 60067
Acura Pharmaceuticals Inc is a drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications. It has discovered and developed three proprietary platform technologies which can be used to develop multiple products. Its Limitx Technology is being developed to minimize the risk of overdose, its Aversion Technology is intended to address methods of abuse associated with opioid analgesics while its Impede Technology is directed at minimizing the extraction and conversion of pseudoephedrine, or PSE, into methamphetamine. It operates in single segment being the research, development and commercialization of technologies and products intended to address safe use of medications.
16GF Score

Get the complete analysis for STU:HD4B

Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.20
Price